Enzymotec Ltd. Announces Departure of its CEO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Enzymotec (ENZY) Misses Q3 EPS by 4c; Trims FY16 Outlook; CEO Katz Resigns
November 16, 2016 7:33 AM ESTEnzymotec (NASDAQ: ENZY) reported Q3 EPS of $0.03, $0.04 worse than the analyst estimate of $0.07. Revenue for the quarter came in at $11.4 million versus the consensus estimate of $13.3 million.
CEO Change:
Enzymotec also announced that Dr. Ariel Katz, the Companys President and Chief Executive Officer, will depart the Company by the end of May 2017, and the Board of Directors has initiated a... More
